Gene Therapy Clinical Trials
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- biological: rituximab
- drug: cytarabine
- drug: dexamethasone
- drug: methotrexate
- drug: Leucovorin
- drug: Procarbazine
- drug: Vincristine
Eligibility
Inclusion criteria:
- Histologically confirmed non-Hodgkin's lymphoma by brain biopsy
- Patients with inconclusive biopsy or patients who are not candidates for biopsy must
have typical CT scan or MRI of the brain AND meet ≥ 1 of the following criteria:
- Positive cerebrospinal fluid cytology for lymphoma OR a monoclonal lymphoid
population as defined by cell surface markers or immunoglobulin gene
rearrangement studies
- Biopsy-proven involvement of the vitreous or uvea if cells are apparent in the
posterior chamber or vitreous by ophthalmological examination
- Bideminsionally measurable disease, defined as contrast-enhancing tumor ≥ 1 cm by
pretreatment MRI/CT scan
- Meningeal or vitreous involvement constitutes evaluable but not measurable
disease
- If an excisional, rather than a needle biopsy was done, measurable disease must
be present on a postoperative scan (not a PET-CT scan)
- ECOG performance status 0-3
- Absolute granulocyte count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin ≤ upper limit of normal (ULN)
- SGOT ≤ 2.0 times ULN
- Creatinine clearance ≥ 50 mL/min
- Negative pregnancy test
- Fertile patients must use effective contraception
Exclusion criteria:
- Pregnant or nursing
- HIV-1 positivity
- Other malignancy within the past 5 years except basal cell skin cancer or any
carcinoma in situ
- Pre-existing immunodeficiency
- Hepatitis B surface antigen positivity
- Systemic lymphoma (as determined by pre-registration CT scans and physical
examination)
- Prior chemotherapy or radiotherapy for primary central nervous system lymphoma
- Prior organ or bone marrow transplantation
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting